NCT00796029View on ClinicalTrials.gov

A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Schizophrenia
Interventions
DRUG

14C-paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00796029 - A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose | Biotech Hunter | Biotech Hunter